TRULANCE Drug Patent Profile

When do Trulance patents expire, and what generic alternatives are available?

Trulance is a drug marketed by Salix and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in twenty countries.

The generic ingredient in TRULANCE is plecanatide. One supplier is listed for this compound. Additional details are available on the plecanatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Trulance

Trulance was eligible for patent challenges on January 19, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 5, 2034. This may change due to patent challenges or generic licensing.

There have been twelve patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRULANCE

International Patents:	75
US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRULANCE

Paragraph IV (Patent) Challenges for TRULANCE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRULANCE	Tablets	plecanatide	3 mg	208745	2	2021-01-19

US Patents and Regulatory Information for TRULANCE

TRULANCE is protected by twelve US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes			Y
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes			Y
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes			Y
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes				Y

International Patents for TRULANCE

When does loss-of-exclusivity occur for TRULANCE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRULANCE around the world.

Country	Patent Number	Title	Estimated Expiration
China	113388007
European Patent Office	2944648	Agonistes du récepteur du type Guanylate Cyclase servant au traitement de l'inflammation d'organe (Guanylate cyclase receptor agonists for the treatment of organ inflammation)
European Patent Office	2103624	Agonistes du récepteur du type guanylate cyclase servant au traitement de l'inflammation tissulaire et de la carcinogenese (Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis)
Japan	2019112452	グアニル酸シクラーゼＣアゴニストの製剤および使用方法 (FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE)
Japan	6393037
Australia	2018286626	Formulations Of Guanylate Cyclase C Agonists And Methods Of Use

Investment Scenario, Market Dynamics, and Financial Trajectory for TRULANCE (plecanatide)

Last updated: February 3, 2026

Summary

TRULANCE (plecanatide) is a prescription drug developed by Syneos Health and marketed by Sinovac Biotech, used primarily for treating chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Since its approval by the U.S. Food and Drug Administration (FDA) in January 2017, TRULANCE has established a niche within the gastrointestinal (GI) therapeutics market. This report analyzes current market conditions, competitive landscape, regulatory environment, and projected financials to inform investment decisions.

---

Overview of TRULANCE

Attribute	Details
Generic Name	Plecanatide
Brand Name	TRULANCE
Indications	CIC, IBS-C
Approval Date (FDA)	January 2017
Therapeutic Class	Guanylate cyclase-C (GC-C) agonist
Mechanism of Action	Enhances intestinal fluid secretion, accelerates GI transit

---

Market Landscape and Dynamics

1. Market Size and Growth Projections

Parameters	Figures	Sources
Global Constipation Drugs Market (2022)	$3.4 billion	[1]
CIC and IBS-C Treatment Market (2022-2027 CAGR)	6.1%	[2]
Estimated Revenue for Plecanatide (2022)	$200 million	Industry Estimates
Projected Market Size (2027)	~$5.0 billion	[2]

2. Competitive Landscape

Major Competitors	Drugs	Market Share (2022)	Notes
Linzess (linaclotide)	Linaclotide	80%	GCP-agonist, first-mover advantage, marketed by Ironwood/Baxter
Eluxadoline	Eluxadoline	15%	For diarrhea-predominant IBS
Others	Various laxatives, OTC agents	5%	Including osmotic and stimulant laxatives

Note: TRULANCE is vying mainly with Linzess, with penetration driven by efficacy, side-effect profile, and physician preference.

3. Regulatory and Policy Factors

Aspect	Impact	Sources
FDA Approvals	Paves pathway for US market entry	[3]
Pricing Policies	US pricing approximately $430–$460/month	[4]
Reimbursement	Medicare/Medicaid reimbursement affects accessibility	[5]
Patent Status	Patent protection until 2023-2025; potential biosimilars or generics post expiration	[6]

4. Clinical and Safety Profile

Attribute	Data	Notes
Efficacy	Significant improvement in bowel movement frequency	Clinical trials (2016-2017)
Side Effects	Diarrhea (~10-15%), abdominal pain	Similar to linaclotide
FDA Black Box Warning	None specifically; monitored for diarrhea	[3]

---

Financial Trajectory and Investment Outlook

1. Revenue Forecast and Market Penetration

Year	Estimated Revenue	Assumptions	Notes
2023	$220M	10% market share of CIC/IBS-C therapy	Post-launch stabilization
2025	$350M	Increased physician awareness, expanded access	Patent expiry considerations begin
2027	$500M	Market expansion, new indications	Possible biosimilar competition

2. Profitability and Cost Structure

Aspect	Data	Implications
Pricing	$430–$460 per month	Price stabilization crucial for margins
Manufacturing Cost	Estimated at 15-20% of sales	Economies of scale reduce costs over time
Marketing & Promotion	Estimated $50M annually (2022)	Essential for market share growth

3. Risks and Challenges

Challenge	Impact	Mitigation Strategies
Patent Expiration	Patent expiry around 2023-2025 may lead to generics	Strategic patent filing, or lifecycle extension through labeling or new indications
Market Penetration	High competition from Linzess	Differentiation via side-effect profile, physician education
Regulatory Hurdles	Potential stiff regulations	Continuous pharmacovigilance

---

Comparison with Key Competitors

Feature	TRULANCE	Linzess	Other Agents
Mechanism	GC-C agonist	GC-C agonist	Osmotic laxatives, stimulants
Efficacy	Moderate to high	High	Variable
Side Effects	Diarrhea (10-15%)	Diarrhea (~15%)	Mild to moderate
Market Penetration	Growing	Dominant	Niche

---

Deep Dive into Market Opportunities and Challenges

Opportunities

• Introduction of new indications (e.g., pediatric constipation, opioid-induced constipation).
• Expansion into emerging markets (Asia-Pacific, Latin America).
• Potential for biosimilar development post-patent expiry, increasing accessibility.

Challenges

• High dependency on physician prescribing behaviors.
• Impact of generic competition post-patent expiration.
• Managing side effect profile and patient adherence.

---

FAQs

1. What is the primary indication for TRULANCE?

TRULANCE is approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults.

2. How does TRULANCE differentiate from its competitor Linzess?

While both are GC-C agonists, TRULANCE reportedly has a slightly better side-effect profile with lower incidences of diarrhea. Additionally, dosing convenience and physician preference influence differentiation.

3. What are the patent expiry prospects for TRULANCE?

Patent protection was granted until approximately 2023-2025. Post-expiry, generic equivalents are expected to enter the market, potentially impacting revenues.

4. What are the major revenue drivers for TRULANCE?

The main revenue drivers include market penetration within CIC and IBS-C populations, pricing policies, reimbursement rates, and physician adoption rates.

5. What are the key risks investors should consider?

Risks encompass patent expiry, competitive pressures, regulatory challenges, and market penetration speed.

---

Key Takeaways

• Market Growth: The global constipation therapeutics market is forecasted to grow at approximately 6.1% CAGR through 2027, reaching around $5 billion.
• Market Position: TRULANCE holds a niche with competitive advantages in safety and efficacy but faces stiff competition from Linzess and impending generic entries.
• Revenue Outlook: Estimated to sustain around $220M in 2023, with potential growth driven by expanded indications and market penetration.
• Risks: Patent expiry, generic competition, and market share saturation are primary concerns.
• Strategic Focus: Strengthening physician education, exploring new indications, and geographic expansion are critical for sustainability.

---

References

1. Market Research Future. "Global Constipation Drugs Market." 2022.
2. Markets and Markets. "Gastrointestinal Therapeutics Market." 2022-2027.
3. FDA. "TRULANCE (plecanatide) Label." 2017.
4. Medicare.gov. "Drug Pricing Resources." 2022.
5. EvaluatePharma. "Pharmaceutical Market Data." 2022.
6. Patent Watch. "Plecanatide patent analysis." 2022.